Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloablative vs nonmyeloablative transplantation in MDS or AML
2006-001075-37Phase 3Completed
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of busulfan, cyclophosphamide, fludarabine, cyclosporine, mycophenolate mofetil in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Started Apr 2007; status: completed.
02
Drugs
busulfancyclophosphamidefludarabinecyclosporinemycophenolate mofetil
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-001075-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001075-37.